{
    "nctId": "NCT01137994",
    "briefTitle": "A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer",
    "officialTitle": "A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-line Treatment for Women With HER2-positive and p95HER2-positive Metastatic Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Neoplasms, Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Progression-free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female \u2265 18 years of age\n* Histologically or cytologically confirmed invasive breast cancer with distant metastasis(ses) (designated as Stage IV or metastatic breast cancer)\n\n  * Diagnosis with Stage IV or metastatic disease at either primary diagnosis or recurrence\n* Not received prior systemic or local treatment (e.g., chemotherapy, endocrine or radiotherapy) for Stage IV/metastatic breast cancer\n\n  * Prior adjuvant and/or neo-adjuvant therapy is permitted\n* Documentation of HER2 overexpression or gene amplification, in the invasive component of either a metastatic disease site or primary tumor, defined as: 3+ by IHC and/or HER2/neu gene amplification by fluorescence, chromogenic or silver in situ hybridization \\[FISH, CISH or SISH; \\>6 HER2/neu gene copies per nucleus or a FISH, CISH or SISH test ratio (HER2 gene copies to chromosome 17 signals) of \u22652.0\\]\n* Documentation by the central laboratory of positive p95HER2 expression in the invasive component of either a metastatic disease site (preferred) or primary tumor\n* No history of CNS metastases (including leptomeningeal involvement) or stable CNS metastases (defined as asymptomatic and off steroids for \u2265 3 months)\n* Baseline Left Ventricular Ejection Fraction (LVEF) \u226550% measured by echocardiography (ECHO) or multi-gated acquisition scan (MUGA)\n* Recovered or stabilized from all adverse events associated with prior anti-cancer therapies, including radiotherapy, at the time of screening\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2\n* Have adequate marrow and organ function as defined as:\n\nSYSTEM LABORATORY VALUES Hematologic ANC \u22651.5 x 109/L Hemoglobin \u22659 g/dL (after transfusion if needed) Platelets \u2265100 x 109/L Hepatic Albumin \u2265 2.5 g/dL Serum bilirubin \u22641.5 x ULN unless due to Gilbert's syndrome AST and ALT \u22643 x ULN Renal Calculated creatinine clearance \u2265 40 mL/min Serum Creatinine \u22641.5 mg/dL or 132.6\u00b5mol/L (Abbreviations: ANC, absolute neutrophil count; ULN, upper limit of normal; AST, aspartate aminotransferase; ALT, alanine aminotransferase)\n\n* Women of childbearing potential, including women whose last menstrual period was \\<12 months ago (unless surgically sterile) must have a negative serum pregnancy test and agree to use effective contraception, as defined in protocol\n* Signed Informed Consent Form\n\nExclusion Criteria:\n\n* History of other malignancy. Exception: Subjects who have been disease-free for 5 years or subjects with a history of completely resected non-melanoma skin cancer (basal or squamous) are eligible\n* Concurrent anti-cancer treatment or concurrent treatment with an investigational drug\n* Administration of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment\n* Prior treatment with anti-HER2 therapy, except trastuzumab or lapatinib (time from last dose of trastuzumab or lapatinib to randomization must be \u22653 months)\n* Serious cardiac illness or medical condition including but not confined to:\n\n  * Uncontrolled arrhythmias\n  * Uncontrolled or symptomatic angina\n  * History of congestive heart failure (CHF)\n  * Documented myocardial infarction \\<6 months from study entry\n* Current active hepatic or biliary disease (with exception of Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)\n* Concurrent disease or condition, or any pre-existing medical disorder that in the opinion of the investigator may interfere with the subject's safety, obtaining informed consent or compliance to the study procedures\n* Pregnant or lactating female\n* Any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels (consult with GSK Medical Monitor if uncertain about eligibility)\n* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to any of the study drugs or their excipients that, in the opinion of the investigator contra-indicates participation",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}